高水平论文推送7——肿瘤学
各单位、部门，全体科研人员：
为促进学术交流与知识共享，助力科研人员及时了解各领域前沿动态与最新研究成果，现决定定期推送现金体育网_bob电竞体育博彩￥官网app平台学者发表的高水平论文。每篇推送将包含论文题目、作者信息、发表期刊/会议、核心观点摘要、研究亮点及创新点等关键内容。
本期主题为肿瘤学，希望为相关研究者的学术研究提供有益参考，提升学术水平。请有关单位、部门加强学校高水平论文的推介工作。
科学技术部
2025年9月13日
缺氧增强的YAP1-EIF4A3相互作用通过竞争性结合CRIM1前体mRNA抑制其线性剪接，驱动circ_0007386环化并促进非小细胞肺癌进展
Issue JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 2024, Volume 43 Issue 1
期刊：《实验与临床癌症研究杂志》2024年，第43卷第1期
Author Li Lixia / Liu Dewei / Chen Tingting / Wei Chunhui / Qiao Youping / Liu Weiliang / Liang Yanmei / Liang Zhu / Chen Chunyuan / Li Dongming / Wu Bin / Zhao Xuanna / Huang Dan / Wu Dong
Keywords Non-small cell lung cancer / Circ_0007386 / miR-383-5p / CIRBP / YAP1 / Apoptosis / Proliferation / Hypoxia
Abstract
Background The progression of non-small cell lung cancer (NSCLC) is significantly influenced by circular RNAs (circRNAs), especially in tumor hypoxia microenvironment. However, the precise functions and underlying mechanisms of dysregulated circRNAs in NSCLC remain largely unexplored. Methods Differentially expressed circRNAs in NSCLC tissues were identified through high-throughput RNA sequencing. The characteristics of circ_0007386 were rigorously confirmed via Sanger sequencing, RNase R treatment and actinomycin D treatment. The effects of circ_0007386 on proliferation and apoptosis were investigated using CCK8, cloning formation assays, TUNEL staining, and flow cytometry assays in vitro. In vivo, xenograft tumor models were used to evaluate its impact on proliferation. Mechanistically, the regulatory relationships of circ_0007386, miR-383-5p and CIRBP were examined through dual luciferase reporter assays and rescue experiments. Additionally, we detected the binding of EIF4A3 to CRIM1 pre-mRNA by RNA immunoprecipitation and the interaction between YAP1 and EIF4A3 under hypoxic conditions by co-immunoprecipitation. Results Our investigation revealed a novel circRNA, designated as circ_0007386, that was upregulated in NSCLC tissues and cell lines. Circ_0007386 modulated proliferation and apoptosis in NSCLC both in vitro and in vivo. Functionally, circ_0007386 acted as a sponge for miR-383-5p, targeting CIRBP, which influenced NSCLC cell proliferation and apoptosis via the PI3K/AKT signaling pathway. Furthermore, under hypoxic conditions, the interaction between YAP1 and EIF4A3 was enhanced, leading to the displacement of EIF4A4 from binding to CRIM1 pre-mRNA. This facilitated the back-splicing of CRIM1 pre-mRNA, increasing the formation of circ_0007386. The circ_0007386/miR-383-5p/CIRBP axis was significantly associated with the clinical features and prognosis of NSCLC patients. Conclusions Circ_0007386, regulated by YAP1-EIF4A3 interaction under hypoxia conditions, plays an oncogenic role in NSCLC progression via the miR-383-5p/CIRBP axis.
Cite this article as: [1]Li Lixia, Liu Dewei, Chen Tingting, et al.Hypoxia-enhanced YAP1-EIF4A3 interaction drives circ_0007386 circularization by competing with CRIM1 pre-mRNA linear splicing and promotes non-small cell lung cancer progression[J].JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH,2024,43(1).
长期表达性书写对化疗期乳腺癌患者健康结局的影响：一项多中心随机对照试验
Issue SUPPORTIVE CARE IN CANCER 2020, Volume 29 Issue 2 1091-1101
期刊：《癌症支持治疗》2020年，第29卷第2期，1091-1101页
Author Wu Yanni / Liu Liping / Zheng Wanting / Zheng Chunrao / Xu Min / Chen Xiaohong / Li Wenji / Xie Lijun / Zhang Pengyan / Zhu Xiaoli / Zhan Chuanglian / Zhou Chunlan
Keywords Breast cancer / Chemotherapy / Expressive writing / Quality of life / Nursing practice
Abstract
Purpose This study aims to evaluate the effects of prolonged expressive writing on health outcomes in breast cancer patients undergoing chemotherapy to help understand how the dosage of an expressive writing intervention might moderate its effects. Methods A total of 112 breast cancer patients undergoing chemotherapy were randomly allocated to the expressive writing group (n = 56) or the prolonged expressive writing group (n = 56). The expressive writing group received the standard expressive writing intervention based on Pennebaker's prompt to write for at least 20 min over four consecutive days (4 sessions). The prolonged expressive writing group used a modified prompt: write for at least 20 min 3 times a week over a 4-week period (12 sessions); patients could choose whether to write on consecutive days or not. All participants were required to write about their stressor-related upsetting or traumatic feelings about breast cancer. Outcomes were assessed and compared at baseline, as well as 1 month, 3 months, and 6 months postintervention. Results There was no significant difference in the patients' quality of life, or physical and psychological wellbeing between the expressive writing group and the prolonged expressive writing group at any time point (allp > .05). The quality of life of breast cancer patients significantly decreased in the two groups over time (F = 40.64,p < .001). Conclusion Our findings suggest that the writing dosage does not moderate the effects of expressive writing on breast cancer patients undergoing chemotherapy.
Cite this article as: [1]Wu Yanni, Liu Liping, Zheng Wanting, et al.Effect of prolonged expressive writing on health outcomes in breast cancer patients receiving chemotherapy: a multicenter randomized controlled trial[J].SUPPORTIVE CARE IN CANCER,2020,29(2):1091-1101.
Discovery of the hidden coding information in cancers: Mechanisms and biological functions
癌症中 “隐藏” 编码信息的发现：机制与生物学功能
Issue INTERNATIONAL JOURNAL OF CANCER 2022, Volume 153 Issue 1 20-32
期刊：《国际癌症杂志》2022年，第153卷第1期，20-32页
Author Zhou Xiaoling / Wu Xiang / Lai Kairan / Zhou Ruiyao / Chen Zhanghui / Yang Zhigang / Gao Xiangwei
Keywords 5 ' UTR / cancer / micropeptide / ncRNA / noncanonical translation
Abstract
Most proteins are derived from the translation of coding sequence (CDS) in messenger RNAs (mRNAs). However, accumulating evidence has revealed an unexpected abundance of translation in putative non-coding genomes, especially 5'' untranslated region (5 & PRIME; UTR) of mRNAs or non-coding RNA species (ncRNA) such as long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs). Notably, many of these UTR- or ncRNA-encoded micropeptides/proteins play important roles in human malignancies. In this review, we describe recent advances in our understanding of the mechanisms underlying the translation of non-coding regions or ncRNAs and the methods to discover the hidden coding information. Furthermore, we summarize the biological functions of UTR- or ncRNA-encoded micropeptides/proteins in cancers and discuss their potential as clinical biomarkers for cancer diagnosis and as therapeutic targets for cancer treatment.
Cite this article as: [1]Zhou Xiaoling, Wu Xiang, Lai Kairan, et al.Discovery of the hidden coding information in cancers: Mechanisms and biological functions[J].INTERNATIONAL JOURNAL OF CANCER,2022,153(1):20-32.
乳腺癌脑转移肿瘤微环境中神经胶质细胞与免疫细胞的分析
Issue CANCER BIOLOGY & THERAPY 2024, Volume 25 Issue 1
期刊：《癌症生物学与治疗》2024年，第25卷第1期
Author Mo Haixin / Zhang Xin / Ren Liangliang
Keywords Breast cancer / brain metastasis / tumor microenvironment / neuroglia / immune cells
Abstract
Breast cancer stands as the most prevalent cancer diagnosed worldwide, often leading to brain metastasis, a challenging complication characterized by high mortality rates and a grim prognosis. Understanding the intricate mechanisms governing breast cancer brain metastasis (BCBM) remains an ongoing challenge. The unique microenvironment in the brain fosters an ideal setting for the colonization of breast cancer cells. The tumor microenvironment (TME) in brain metastases plays a pivotal role in the initiation and progression of BCBM, shaping the landscape for targeted therapeutic interventions. Current research primarily concentrates on unraveling the complexities of the TME in BCBM, with a particular emphasis on neuroglia and immune cells, such as microglia, monocyte-derived macrophages (MDMs), astrocytes and T cells. This comprehensive review delves deeply into these elements within the TME of BCBM, shedding light on their interplay, mechanisms, and potential as therapeutic targets to combat BCBM.
Cite this article as: [1]Mo Haixin, Zhang Xin, Ren Liangliang.Analysis of neuroglia and immune cells in the tumor microenvironment of breast cancer brain metastasis[J].CANCER BIOLOGY & THERAPY,2024,25(1).
剪接因子TRA2A通过在长链非编码RNA的m6A甲基化中发挥非经典作用促进食管癌进展
Issue CANCER SCIENCE 2023, Volume 114 Issue 8 3216-3229
期刊：《癌症科学》2023年，第114卷第8期，3216-3229页
Author Bei Mingrong / Hao Shijia / Lin Kai / Chen Qiuyang / Cai Yujie / Zhao Xing / Jiang Leiming / Lin Lirui / Dong Geng / Xu Jianzhen
Keywords esophageal cancer / LncRNA methylation / MALAT1 / splicing factor / TRA2A
Abstract
Transformer 2 alpha homolog (TRA2A), a member of the serine/arginine-rich splicing factor family, has been shown to control mRNA splicing in development and cancers. However, it remains unclear whether TRA2A is involved in lncRNA regulation. In the present study, we found that TRA2A was upregulated and correlated with poor prognosis in esophageal cancer. Downregulation of TRA2A suppressed the tumor growth in xenograft nude mice. Epitranscriptomic microarray showed that depletion of TRA2A affected global lncRNA methylation similarly to the key m(6)A methyltransferase, METTL3, by silencing. MeRIP-qPCR, RNA pull-down, CLIP analyses, and stability assays indicated that ablation of TRA2A reduced m(6)A-modification of the oncogenic lncRNA MALAT1, thus inducing structural alterations and reduced stability. Furthermore, Co-IP experiments showed TRA2A directly interacted with METTL3 and RBMX, which also affected the writer KIAA1429 expression. Knockdown of TRA2A inhibited cell proliferation in a manner restored by RBMX/KIAA1429 overexpression. Clinically, MALAT1, RBMX, and KIAA1429 were prognostic factors of worse survival in ESCA patients. Structural similarity-based virtual screening in FDA-approved drugs repurposed nebivolol, a ss 1-adrenergic receptor antagonist, as a potent compound to suppress the proliferation of esophageal cancer cells. Cellular thermal shift and RIP assay indicated that nebivolol may compete with MALAT1 to bind TRA2A. In conclusion, our study revealed the noncanonical function of TRA2A, which coordinates with multiple methylation proteins to promote oncogenic MALAT1 during ESCA carcinogenesis.
Cite this article as: [1]Bei Mingrong, Hao Shijia, Lin Kai, et al.Splicing factor TRA2A contributes to esophageal cancer progression via a noncanonical role in lncRNA m6A methylation[J].CANCER SCIENCE,2023,114(8):3216-3229.
DDIT4作为三阴性乳腺癌化疗及免疫治疗反应相关潜在预后标志物的鉴定
Issue WORLD JOURNAL OF SURGICAL ONCOLOGY 2023, Volume 21 Issue 1
期刊：《世界外科肿瘤学杂志》2023年，第21卷第1期
Author Chen Xuanzhao / Li Zeyan / Liang Meihua / Zhang Ziyang / Zhu Di / Lin Biyun / Zhou Renyu / Lu Yuanzhi
Keywords TNBC / Bioinformatics / Prognosis / Targeting therapy / Immune microenvironment
Abstract
BackgroundTriple-negative breast cancer (TNBC) is the most heterogenous and aggressive subtype of breast cancer. Chemotherapy remains the standard treatment option for patients with TNBC owing to the unavailability of acceptable targets and biomarkers in clinical practice. Novel biomarkers and targets for patient stratification and treatment of TNBC are urgently needed. It has been reported that the overexpression of DNA damage-inducible transcript 4 gene (DDIT4) is associated with resistance to neoadjuvant chemotherapy and poor prognosis in patients with TNBC. In this study, we aimed to identify novel biomarkers and therapeutic targets using RNA sequencing (RNA-seq) and data mining using data from public databases.MethodsRNA sequencing (RNA-Seq) was performed to detect the different gene expression patterns in the human TNBC cell line HS578T treated with docetaxel or doxorubicin. Sequencing data were further analyzed by the R package "edgeR" and "clusterProfiler" to identify the profile of differentially expressed genes (DEGs) and annotate gene functions. The prognostic and predictive value of DDIT4 expression in patients with TNBC was further validated by published online data resources, including TIMER, UALCAN, Kaplan-Meier plotter, and LinkedOmics, and GeneMANIA and GSCALite were used to investigate the functional networks and hub genes related to DDIT4, respectively.ResultsThrough the integrative analyses of RNA-Seq data and public datasets, we observed the overexpression of DDIT4 in TNBC tissues and found that patients with DDIT4 overexpression showed poor survival outcomes. Notably, immune infiltration analysis showed that the levels of DDIT4 expression correlated negatively with the abundance of tumor-infiltrating immune cells and immune biomarker expression, but correlated positively with immune checkpoint molecules. Furthermore, DDIT4 and its hub genes (ADM, ENO1, PLOD1, and CEBPB) involved in the activation of apoptosis, cell cycle, and EMT pathways. Eventually, we found ADM, ENO1, PLOD1, and CEBPB showed poor overall survival in BC patients.ConclusionIn this study, we found that DDIT4 expression is associated with the progression, therapeutic efficacy, and immune microenvironment of patients with TNBC, and DDIT4 would be as a potential prognostic biomarker and therapeutic target. These findings will help to identify potential molecular targets and improve therapeutic strategies against TNBC.
Cite this article as: [1]Chen Xuanzhao, Li Zeyan, Liang Meihua, et al.Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer[J].WORLD JOURNAL OF SURGICAL ONCOLOGY,2023,21(1).
巴塞罗那临床肝癌分期0/A期破裂型肝细胞癌的肝切除术治疗：最佳治疗方案
Issue EJSO 2022, Volume 48 Issue 9 2014-2022
期刊：《欧洲外科肿瘤学杂志》2022年，第48卷第9期，2014-2022页
Author Xia Feng / Huang Zhiyuan / Zhang Qiao / Ndhlovu Elijah / Zhang Mingyu / Chen Xiaoping / Chen Yifa / Zhang Bixiang / Zhu Peng
Keywords BCLC stage / Hepatectomy / Ruptured hepatocellular carcinoma / TNM stage
Abstract
Background and aims: Ruptured hepatocellular carcinoma (rHCC) generally has a very poor prognosis and is currently classified as T4 in the tumorenodeemetastasis (TNM) staging system. In this study, we aimed to demonstrate the actual impact of rHCC, as well as the positive effect of hepatectomy in patients with Barcelona Clinic Liver Cancer (BCLC) stage 0/A rHCC. Methods: We enrolled 86 patients with rHCC after surgery and 526 patients with non-rHCC after surgery or transcatheter arterial chemoembolization (TACE). Survival curves were plotted using the Kaplan eMeier method to compare the postoperative prognosis of patients with rHCC with that of patients with non-rHCC. Univariate and multivariate Cox regression analyses were used to identify the risk factors affecting patient survival. Results: BCLC stage 0/A rHCC treated with surgery had a worse prognosis than BCLC stage 0/A non-rHCC treated with surgery (overall survival [OS]: hazard ratio [HR] = 3.12 [2.24e4.34], P < 0.001; recurrencefree survival [RFS]: HR = 2.26 [1.65e3.09], P < 0.001). Rupture was an independent prognostic factor in patients with BCLC stage 0/A rHCC (OS: HR = 1.685 [1.416e2.006], P < 0.001; RFS: HR = 1.484 [1.267 e1.737], P < 0.001), and patients with BCLC stage 0/A rHCC who underwent surgery had a comparable prognosis to patients with BCLC stage B HCC who underwent surgery or TACE (OS: P = 0.78). Conclusions: Patients classified as having BCLC stage 0/A rHCC can achieve comparable outcomes to patients with BCLC stage B HCC after hepatectomy. However, not all patients with rHCC should be classified as T4 in the TNM staging system. (c) 2022 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Cite this article as: [1]Xia Feng, Huang Zhiyuan, Zhang Qiao, et al.Hepatectomy for ruptured hepatocellular carcinoma classified as Barcelona Clinic Liver Cancer stage 0/A: The optimal treatment[J].EJSO,2022,48(9):2014-2022.
A CT-based radiomics nomogram for differentiation of benign and malignant small renal masses (≤4 cm)
基于计算机断层扫描（CT）的影像组学列线图用于鉴别小肾肿块（≤4cm）良恶性
Issue TRANSLATIONAL ONCOLOGY 2023, Volume 29
期刊：《转化肿瘤学》2023年，第29卷
Author Feng Shengxing / Gong Mancheng / Zhou Dongsheng / Yuan Runqiang / Kong Jie / Jiang Feng / Zhang Lijie / Chen Weitian / Li Yueming
Keywords Kidney neoplasms / Differential / Tomography / Radiomics / Small renal masses
Abstract
Rationale and Objectives: Based on radiomics signature and clinical data, to develop and verify a radiomics nomogram for preoperative distinguish between benign and malignant of small renal masses (SRM).Materials and Methods: One hundred and fifty-six patients with malignant (n = 92) and benign (n = 64) SRM were divided into the following three categories: category A, typical angiomyolipoma (AML) with visible fat; category B, benign SRM without visible fat, including fat-poor angiomyolipoma (fp-AML), and other rare benign renal tumors; category C, malignant renal tumors. At the same time, one hundred and fifty-six patients included in the study were divided into the training set (n = 108) and test set (n = 48). Respectively from corticomedullary phase (CP), nephrogram phase (NP) and excretory phase (EP) CT images to extract the radiomics features, and the optimal features were screened to establish the logistic regression model and decision tree model, and computed the radiomics score (Rad-score). Demographics and CT findings were evaluated and statistically sig-nificant factors were selected to construct a clinical factors model. The radiomics nomogram was established by merging Rad-score and selected clinical factors. The Akaike information criterion (AIC) values and the area under the curve (AUC) were used to compare model discriminant performance, and decision curve analysis (DCA) was used to assess clinical usefulness.Results: Seven, fifteen, nineteen, and seventeen distinguishing features were obtained in the CP, NP, EP, and three-phase joint, respectively, and the logistic regression and decision tree models were built based on this features. In the training set, the logistic regression model works better than the decision tree model for dis-tinguishing categories A and B from category C, with the AUC of CP, NP, EP and three-phase joint were 0.868, 0.906, 0.937 and 0.975, respectively. The radiomics nomogram constructed based on the three-phase joint Rad -score and selected clinical factor performed well on the training set (AUC, 0.988; 95% CI, 0.974-1.000) for differentiation of categories A and B from category C. In the test set, the AUC of clinical factors model, radiomics signature and radiomics nomogram for discriminating categories A and B from category C were 0.814, 0.954 and 0.968, respectively; for the identification of category A from category C, the AUC of the three models were 0.789, 0.979, 0.985, respectively; for discriminating category B from category C, the AUC of the three models were 0.853, 0.915, 0.946, respectively. The radiomics nomogram had better discriminative than the clinical factors model in both training and test sets (P < 0.05). The radiomics nomogram (AIC = 40.222) with the lowest AIC value was considered the best model compared with that of the clinical factors model (AIC = 106.814) and the radiomics signature (AIC = 44.224). The DCA showed that the radiomics nomogram have better clinical utility than the clinical factors model and radiomics signature.Conclusions: The logistic regression model has better discriminative performance than the decision tree model, and the radiomics nomogram based on Rad-score of three-phase joint and clinical factors has a good predictive effect in differentiating benign from malignant of SRM, which may help clinicians develop accurate and indi-vidualized treatment strategies.
Cite this article as: [1]Feng Shengxing, Gong Mancheng, Zhou Dongsheng, et al.A CT-based radiomics nomogram for differentiation of benign and malignant small renal masses (≤4 cm)[J].TRANSLATIONAL ONCOLOGY,2023,29.
预测直肠癌患者回肠造口还纳术后低位前切除综合征（LARS）的新型列线图
Issue EJSO 2023, Volume 49 Issue 2 452-460
期刊：《欧洲外科肿瘤学杂志》2023年，第49卷第2期，452-460页
Author Xia Feng / Zou You / Zhang Qiao / Wu Jianhong / Sun Zhen
Keywords Low anterior resection syndrome / Stoma closure / Rectal cancer / Ileostomy / Nomogram
Abstract
Background and aim: Low anterior resection syndrome (LARS) in patients undergoing low or ultra-low anterior resection (LAR) is a common problem and significantly impacts the quality of life. Patients with an ileostomy after LAR are more likely to develop LARS. However, there hasn't been a model predicting LARS occurrence in these patients. This study aims to construct a nomogram to predict the probability of LARS occurrence in patients with temporary ileostomy and guide preventive strategies before reversal. Methods: 168 patients undergoing LAR with ileostomy from one center were enrolled as the training cohort, and 134 patients of the same inclusion criteria from another center were enrolled as the validation cohort. The training cohort was screened for risk factors for major LARS using univariate and multivariate logistic regression. The nomogram was constructed using the filtered variables, the ROC curve was used to describe the model's discrimination, and the calibration was used to describe the accuracy Results: The optimal cut-off value for stoma closure time was 128 days. Three risk factors were identified using logistic regression analysis: preoperative radiotherapy (OR = 3.038, [95%CI 1.75-5.015], P = 0.005), stoma closure time (OR = 2.298, [95%CI 1.088-4.858], P = 0.029) and pN stage (OR =1.739, [95%CI 1.235 -3.980], P = 0.001). A nomogram was constructed based on these three variables and showed good performance predicting major LARS after stoma reversal. The area under the curve (AUC) was 0.827 in the training group and 0.821 in the validation group; The calibration curve suggested good precision in both groups. Conclusions: This novel nomogram can accurately predict the probability of major LARS occurrence after ileostomy reversal for rectal cancer patients. This model can help screen ileostomy patients with high risks and guide individualized preventive strategies before stoma reversal. (c) 2022 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Cite this article as: [1]Xia Feng, Zou You, Zhang Qiao, et al.A novel nomogram to predict low anterior resection syndrome (LARS) after ileostomy reversal for rectal cancer patients[J].EJSO,2023,49(2):452-460.
